ClinicalTrials.gg
RecruitingNCT05676502NHFDuetUpdated Dec 1, 2023

Effects on Ventilation With NHF and Asymmetrical Nasal Cannulas

An interventional study of AIRVO 2 in Chronic Obstructive Pulmonary Disease, sponsored by Kliniken Essen-Mitte. Recruiting at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-12-01.

Sponsored by Kliniken Essen-Mitte · Not applicable, Interventional, and Treatment

How we know · 3 judgments

From the registry’s dates

  • Primary completion was expected by Jan 2024, 2 years 10 months ago, but the record still lists the study as recruiting.
  • Started Jan 2023; still recruiting 3 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 539 studies in Pulmonary Disease, Chronic Obstructive with a site in Germany — 33 open to participants now, 46 under way, 10 of them phase 3. Pulmonary Disease, Chronic Obstructive · Germany.

Planned enrollment
393rd of 441
20 · median 156
Started
2023
with 15 others
No phase
108 of 539
8 open now
Primary completion
2024-01
later than 1 of 45 live
Registered
486th of 539
by date

Among the 539 studies in Pulmonary Disease, Chronic Obstructive with a site in Germany, this one is the 393rd largest by planned enrollment of the 441 interventional ones that give a count, is one of 16 that started in 2023, is one of 108 with no phase, reaches primary completion later than 1 of the 45 other live ones, and was the 486th registered.

Pulmonary Disease, Chronic Obstructive

5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

33 of the 539 studies in Pulmonary Disease, Chronic Obstructive with a site in Germany are open now. Recruiting first, the newest first:

28 more — sign in →

All 33 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 539 studies in Pulmonary Disease, Chronic Obstructive with a site in Germany, or all of them as a file.
02

Study summary

The aim of this controlled randomized crossover study is to compare the physiological effects of nasal high flow therapy (NHF) with 2 different nasal cannulas in patients with exacerbated chronic obstructive pulmonary disease (ECOPD) and chronic respiratory failure.

20 patients will be treated with NHF therapy (Airvo, Fisher\&Paykel Healthcare, NZ) during wakefulness. Physiological measuremends will take place over three perdiods (visits). One period without NHF, one with NHF via standard cannula (Optiflow M) and one with asymmetrical cannula (Optiflow Duet) in randomised order.

Read the detailed description

Background: Nasal High Flow (NHF) therapy had shown to increase airway pressure, reduce dead space, and improve mucociliary clearance and gas exchange in patients suffering from chronic obstructive pulmonary disease (COPD). The long-term and short-term physiological aspects of NHF are subject of ongoing research. Different flow rates and cannula sizes have been studied and found to yield different therapeutic effects. Larger sized cannulas tend to seal the nares and produce increased positive airway pressure, while smaller cannulas increase the washout effect. Currently, a new cannula is available, with one smaller and one larger opening (Optiflow+ Duet, Fisher\&Paykel Healthcare, NZ).

Procedure: Following a baseline period without high flow therapy, NHF (35L/min) will be applied via the nasal cannula (Duet or Standard in randomized order). After a wash out phase, the NHF interface will be replaced for another measurement with the respective other cannula (Standard or Duet).

Respiratory rate, tidal volume, minute ventilation, inhalation to exhalation ratio (Ti/Te), transcutaneous pCO2 and intercostal EMG will be recorded during each partial measurement.

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease

Keywords

  • Nasal High Flow (NHF)
  • High Flow Nasal Cannula (HFNC)
  • Optiflow
  • COPD
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Inpatients with GOLD 3 and 4 in stable phase after acute exacerbation
  • Inpatients with COPD GOLD (2, 3 and 4)

Exclusion criteria

Exclusion Criteria:

  • Acute respiratory insuffiency with respiratory acidosis (pH\<7.35)
  • Severe acute physical disease, that do not allow the subject to participate in a clinical trial
  • Language, cognitive, or other barriers that make study participation impossible
  • Pregnancy or Nursing
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Active comparator
    Nasal High Flow with Optiflow M cannula

    Nasal high flow treatment 35L/min with the standard symmetric nasal cannula (Optiflow M)

    Device: AIRVO 2

  • Active comparator
    Nasal High Flow with Optiflow Duet Cannula

    Nasal high flow treatment 35L/min with the asymmetric nasal cannula (Optiflow Duet)

    Device: AIRVO 2

Interventions

  • DeviceAIRVO 2

    Patients with chronic obstructive pulmonary disease and chronic respiratory failure use Nasal High Flow therapy during daytime sessions of 1.5 h.

    Also known as: Nasal High Flow

06

What researchers measure

Primary outcomes

  1. Change in minute ventilation (MV) comparing arm 1 and 2

    Respiratory effort measured with calibrated RIP system (Respitrace QDC; Viasys Services, Lakeland, FL), MV is calculated. Unit is L

    Time frame: 1.5 hours

Secondary outcomes

  1. Change in respiratory rate (RR) comparing arm 1 and 2

    Respiratory effort measured with calibrated RIP system (Respitrace QDC; Viasys Services, Lakeland, FL), RR is calculated. Unit is breath per minute

    Time frame: 1.5 hours

  2. Change in inhalation to exhalation ratio (Ti/Te) comparing arm 1 and 2

    Respiratory effort is measured with calibrated RIP system (Respitrace QDC; Viasys Services, Lakeland, FL), (Ti/Te) is calculated.

    Time frame: 1.5 hours

Other outcomes

  1. Change oin intercostal surface EMG (surfEMG) comparing arm 1 and 2

    SurfEMG is measured with EMG system (ADInstruments, NZ), it represents the neural respiratory drive, max ampltude of EMG, unit is mV

    Time frame: 1.5 hours

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2023 (actual). Primary completion is estimated for Jan 2024, 11 months after the start.

Of 1,099 non-industry interventional studies with no phase under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 11 months is below that.

Counting every sponsor, half of 1,187 studies reached it within 22 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 22, 2022
First posted
Jan 9, 2023
StartActual
Jan 19, 2023
Primary completionEst.
Jan 1, 2024
CompletionEst.
Apr 1, 2024
Last update
Dec 1, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 1, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05676502
Lead sponsor
Kliniken Essen-Mitte
Responsible party
Georg Nilius, Prof. Dr. med (Head of Department of Pneumology, PI, Kliniken Essen-Mitte) — Principal investigator
First posted
Jan 9, 2023
Start date
Jan 19, 2023
Primary completion
Jan 1, 2024 (estimated)
Completion
Apr 1, 2024 (estimated)
Last update
Dec 1, 2023

Study contacts

Georg N Nilius, Prof. Dr. med
Contact
G.Nilius@kem-med.com
+49 201 174 ext. 22011
Ulrike Domanski
Contact
U.Domanski@kem-med.com
+49 0201 174 ext. 22058

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion